AR077999A1 - Antagonistas de pirimidin y triazin-hepcidina - Google Patents

Antagonistas de pirimidin y triazin-hepcidina

Info

Publication number
AR077999A1
AR077999A1 ARP100103174A ARP100103174A AR077999A1 AR 077999 A1 AR077999 A1 AR 077999A1 AR P100103174 A ARP100103174 A AR P100103174A AR P100103174 A ARP100103174 A AR P100103174A AR 077999 A1 AR077999 A1 AR 077999A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
hydrogen
heterocyclyl
aryl
Prior art date
Application number
ARP100103174A
Other languages
English (en)
Inventor
Christopher John Yarnold
Vincent Anthony Corden
Stephen Martin Courtney
Tara Fryatt
Franz Durrenberger
Bainbridge Julia Marie Dr
Wilm Buhr
Wei Tsung Yau
Felix Funk
Peter Otto Geisser
Susana Burckhardt
Mark Peter Ridgill
Mark Slack
Stefan Jager
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41490366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of AR077999A1 publication Critical patent/AR077999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Composiciones farmacéuticas que los contienen y su uso como medicamento, particularmente para el tratamiento de desordenes del metabolismo del hierro, particularmente, enfermedades por deficiencia de hierro y anemias, en particular anemia asociada con enfermedad inflamatoria cronica (ACD), anemia de enfermedad cronica y anemia por inflamacion, y los síntomas asociados. Reivindicacion 1: Compuestos de la formula general (1), en que X está elegido del grupo que comprende N o C-R1, estando elegido R1 del grupo que comprende: hidrogeno, hidroxilo, halogeno, carboxilo, radical ácido sulfonico (-SO3H), aminocarbonilo opcionalmente sustituido, aminosulfonilo opcionalmente sustituido, amino opcionalmente sustituido, alquilo opcionalmente sustituido, acilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, aciloxi opcionalmente sustituido, alcoxi opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; R2 y R3 son iguales o distintos entre sí y cada uno de ellos está elegido del grupo que comprende: hidrogeno, hidroxilo, halogeno, carboxilo, radical ácido sulfonico (-SO3H), aminocarbonilo opcionalmente sustituido, aminosulfonilo opcionalmente sustituido, amino opcionalmente sustituido, alquilo opcionalmente sustituido, acilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, aciloxi opcionalmente sustituido, alcoxi opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; Y está elegido del grupo que comprende: hidrogeno, hidroxilo, halogeno, ariloxi opcionalmente sustituido, y el grupo de la formula, -N(R4)(R5) en la cual: R4 y R5 pueden ser iguales o distintos entre sí, y cada uno de ellos está elegido del grupo que comprende: hidrogeno, amino opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, alquilo, arilo o heterociclil-sulfonilo opcionalmente sustituidos, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, acilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido o R4 y R5 conjuntamente con el átomo de nitrogeno al cual están ligados, forman un ciclo saturado o insaturado, opcionalmente sustituido de 3 a 8 miembros, que opcionalmente puede contener otros heteroátomos; o sus sales farmacéuticamente aceptables.
ARP100103174A 2009-09-02 2010-08-30 Antagonistas de pirimidin y triazin-hepcidina AR077999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09169286 2009-09-02

Publications (1)

Publication Number Publication Date
AR077999A1 true AR077999A1 (es) 2011-10-05

Family

ID=41490366

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103174A AR077999A1 (es) 2009-09-02 2010-08-30 Antagonistas de pirimidin y triazin-hepcidina

Country Status (21)

Country Link
US (1) US20120202806A1 (es)
EP (1) EP2473486B2 (es)
JP (1) JP2013503833A (es)
KR (1) KR20120061055A (es)
CN (1) CN102482232A (es)
AR (1) AR077999A1 (es)
AU (1) AU2010291318A1 (es)
BR (1) BR112012008109A2 (es)
CA (1) CA2769553A1 (es)
CL (1) CL2012000591A1 (es)
CR (1) CR20120097A (es)
DO (1) DOP2012000057A (es)
EA (1) EA201200402A1 (es)
ES (1) ES2554855T3 (es)
IL (1) IL218253A0 (es)
MA (1) MA33538B1 (es)
MX (1) MX2012002626A (es)
SG (1) SG178984A1 (es)
TN (1) TN2012000045A1 (es)
TW (1) TW201113272A (es)
WO (1) WO2011026835A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
EP2595965B1 (en) 2010-07-20 2016-06-22 Vestaron Corporation Insecticidal triazines and pyrimidines
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CA2849995A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP2014237590A (ja) * 2011-09-30 2014-12-18 アステラス製薬株式会社 ２−（ピリジン−２−イル）ピリミジン−４−アミン化合物又はその塩
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
DK3459942T3 (da) 2012-04-24 2021-03-08 Vertex Pharma DNA-PK-hæmmere
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014105952A2 (en) * 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
LT3424920T (lt) 2013-10-17 2020-08-10 Vertex Pharmaceuticals Incorporated (s)-n-metil-8-(1-((2`-metil-[4,5`-bipirimidin]-6-il)amino)propan-2-il)chinolin-4-karboksamido ir jo deuterintų darinių, kaip dnr-pk inhibitorių, bendri kristalai
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
MX2019003317A (es) 2016-09-27 2019-08-05 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
ES2906078T3 (es) 2017-01-23 2022-04-13 Cadent Therapeutics Inc Moduladores del canal de potasio
WO2018187652A1 (en) 2017-04-06 2018-10-11 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine h4 modulators
EP3675809B1 (de) 2017-08-31 2023-09-27 Basf Se Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
AU2021263818A1 (en) * 2020-04-28 2022-11-03 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
EP4142732A1 (en) * 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
US20230159553A1 (en) * 2020-04-28 2023-05-25 Global Blood Therapeutics, Inc Thieno pyrimidines as ferroportin inhibitors
CN112028838B (zh) * 2020-08-04 2022-07-01 精华制药集团南通有限公司 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法
CN113683596B (zh) * 2021-08-17 2023-02-10 上海应用技术大学 一种嘧啶类端锚聚合酶2抑制剂及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489591A (en) * 1992-02-28 1996-02-06 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
EP1392345B2 (en) 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
IL162534A0 (en) * 2002-01-02 2005-11-20 Actelion Pharmaceuticals Ltd Novel alkansulfonamides as endotheline antagonists
TW200407315A (en) 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1742634B1 (en) 2004-04-13 2010-10-27 ICAgen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
CA2579472A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
US9771331B2 (en) * 2005-04-22 2017-09-26 The Johns Hopkins University Methods of identifying neuroprotective compounds for retinal ganglion cells
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
JP2009542604A (ja) 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
EP2097084B1 (en) 2006-10-04 2015-01-28 Janssen R&D Ireland Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
EP2111412A2 (en) 2007-02-02 2009-10-28 Amgen, Inc Hepcidin and hepcidin antibodies
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CL2008000666A1 (es) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
AR065785A1 (es) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro
PL2139882T3 (pl) 2007-03-23 2014-05-30 Amgen Inc 3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
WO2008151288A2 (en) 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
KR20100049068A (ko) 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Ｐｋｃ 억제제로서의 시클릭 아민 치환된 피리미딘디아민
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
BRPI0816075A2 (pt) 2007-08-30 2015-02-24 Dow Agrosciences Llc 2-(fenil substituído)-6-amino-5-alcóxi, tioalcóxi e aminoalquil-4-pirimidinacarboxilatos e seus usos como herbicidas
WO2009044284A1 (en) 2007-10-02 2009-04-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies specific for human hepcidin
TWI409276B (zh) 2007-11-02 2013-09-21 Lilly Co Eli 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
US20110124649A1 (en) * 2007-11-09 2011-05-26 The Johns Hopkins University Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
JP5587206B2 (ja) * 2007-12-19 2014-09-10 バーテックス ファーマシューティカルズ インコーポレイテッド ＪＡＫ２阻害剤として有用なピラゾロ［１，５−ａ］ピリミジン
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
CN101938988B (zh) 2008-02-08 2013-06-19 株式会社资生堂 美白剂和皮肤外用剂
ES2524883T3 (es) * 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina

Also Published As

Publication number Publication date
CN102482232A (zh) 2012-05-30
WO2011026835A1 (de) 2011-03-10
ES2554855T3 (es) 2015-12-23
MA33538B1 (fr) 2012-08-01
TN2012000045A1 (en) 2013-09-19
BR112012008109A2 (pt) 2019-09-24
MX2012002626A (es) 2012-04-20
EA201200402A1 (ru) 2012-08-30
EP2473486B1 (de) 2015-10-28
US20120202806A1 (en) 2012-08-09
CA2769553A1 (en) 2011-03-10
CL2012000591A1 (es) 2012-08-03
AU2010291318A1 (en) 2012-03-01
JP2013503833A (ja) 2013-02-04
EP2473486B2 (de) 2021-09-22
SG178984A1 (en) 2012-04-27
EP2473486A1 (de) 2012-07-11
TW201113272A (en) 2011-04-16
DOP2012000057A (es) 2012-08-31
IL218253A0 (en) 2012-04-30
KR20120061055A (ko) 2012-06-12
CR20120097A (es) 2012-09-03

Similar Documents

Publication Publication Date Title
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR077892A1 (es) Quinolinas antagonistas de la hepcidina
SV2016005229A (es) Inhibidores de syk
NI201200044A (es) Compuestos de dióxido de iminotiadiazina como inhibodores de bace , composiciones y su uso
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
NI201400108A (es) Compuestos de heterociclilo
CR20110452A (es) Inhibidores de la poli (adp-ribosa) polimerasa (parp)
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR036586A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
UY29964A1 (es) Formas de cristal f,g,h,i, y k del mesilato de imatinib
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
ECSP11011057A (es) Ácidos naftilacéticos
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída

Legal Events

Date Code Title Description
FA Abandonment or withdrawal